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NOVELTY AND IMPACT 
Our study is the first, to our knowledge, to examine the influence of young-adult onset infectious 
mononucleosis (IM) and other systemic, inflammatory infectious diseases on prostate-specific 
antigen (PSA) levels. Our findings of a rise in PSA during or following IM and other systemic 
infectious diseases in young U.S. military members may have implications for PSA 
interpretation in middle- and older-aged men, among whom PSA is used as a screening test for 
prostate cancer. 
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ABSTRACT 
Although Epstein-Barr virus has been detected in prostate tissue, no associations have been 
observed with prostate cancer in the few studies conducted to date. One possible reason for these 
null findings may be use of cumulative exposure measures that do not inform the timing of 
infection, i.e., childhood versus adolescence/early-adulthood when infection is more likely to 
manifest as infectious mononucleosis (IM). We sought to determine the influence of young 
adult-onset IM on the prostate by measuring prostate-specific antigen (PSA) as a marker of 
prostate inflammation/damage among U.S. military members. We defined IM cases as men 
diagnosed with IM from 1998-2003 (n=55) and controls as men without an IM diagnosis 
(n=255). We selected two archived serum specimens for each participant, the first collected after 
diagnosis for cases and one randomly-selected from 1998-2003 for controls (“index”), as well as 
the preceding specimen (“pre-index”). PSA was measured in each specimen. To explore the 
specificity of our findings for prostate as opposed to systemic inflammation, we performed a 
post-hoc comparison of other infectious disease cases without genitourinary involvement (n=90) 
and controls (n=220). We found that IM cases were more likely to have a large PSA rise than 
controls (≥20 ng/mL: 19.7% versus 8.8%, p=0.027; ≥40% rise: 25.7% versus 9.4%, p=0.0021), 
as were other infectious disease cases (25.7% versus 14.0%, p=0.020; 27.7% versus 18.0%, 
p=0.092). These findings suggest that, in addition to rising because of prostate infection, PSA 
may also rise because of systemic inflammation, which could have implications for PSA 
interpretation in older men.  
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INTRODUCTION 
Infection with Epstein-Barr virus (EBV), a member of the gamma herpesvirus family, has 
been shown to contribute to the development of several cancers, including Burkitt’s lymphoma 
and nasopharyngeal carcinoma.1 Few studies have investigated EBV infection in relation to other 
cancers, such as prostate cancer. Evidence of EBV infection has been detected in at least five 
studies of benign and/or neoplastic prostate tissue,2-6 although it was not associated with prostate 
cancer risk in one of these studies.2 Two additional studies investigated EBV serology and 
prostate cancer with null or generally unstable results.7,8 However, it is possible these studies 
may have missed an association if the timing of EBV infection is important for carcinogenesis.9 
For instance, whereas childhood EBV infections typically result in mild or no symptoms, 
infections acquired later in adolescence or early-adulthood are more likely to result in infectious 
mononucleosis (IM), a clinical syndrome characterized by symptoms of sore throat, malaise, and 
fatigue; and signs of pharyngitis, fever, and lymphadenopathy.10 These later-onset infections 
have been found to be important for risk of certain conditions, such as multiple sclerosis,11 and 
could also be important for other conditions, such as prostate cancer.   
To begin to explore this hypothesis, we investigated the extent of prostate pathogenesis 
during young adult-onset IM by measuring prostate-specific antigen (PSA) concentration as a 
marker of prostate inflammation and cell damage in young IM cases and controls with stored 
sera in the Department of Defense Serum Repository (DoDSR12). We used serum PSA as a 
marker of prostate inflammation/cell damage because PSA has been shown to be elevated in men 
with acute bacterial prostatitis and asymptomatic histologic prostate inflammation.13 In previous 
studies using this marker,14 including one using stored DoDSR specimens,15 we found that men 
with exudative sexually transmitted infections (STIs), such as chlamydia and gonorrhea, were 
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more likely to have a large rise in PSA (defined by a ≥40% increase in PSA) at the time of 
infection than men with no STI diagnoses, suggesting that prostate infection, inflammation, 
and/or cell damage occur in some men infected with sexually transmitted agents. In the present 
study, we sought to determine whether similar findings were observed for young adult-onset IM. 
In addition, because IM contributes to both organ-specific and systemic inflammation, we 
performed a post-hoc analysis of other infectious diseases and PSA to begin to explore the 
specificity of observed associations for prostate inflammation/cell damage as opposed to 
systemic or other non-prostate inflammation. 
 
METHODS  
Study population and design 
The DoDSR contains sera remaining from routine human immunodeficiency virus type 1 
(HIV-1) testing of all U.S. military personnel since the early 1990s. It also contains sera 
remaining from indicated HIV-1 testing (e.g., as part of standard clinical work-up for STIs), and 
sera collected for pre- and post-deployment sero-surveillance.16 Sera are linked to a relational 
database that contains information on demographics, service-related activity, and medical 
diagnoses for all active duty service members. Medical diagnoses are recorded as International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coded records.12,17 
IM is diagnosed in several ways in the military, including the Monospot® test, EBV antibody-
specific tests, and symptoms; however, the method of diagnosis is not recorded. 
For the present analysis, we required participants to be 18-25 years of age as of 1995, to 
be HIV-negative, and to have served on continuous active military duty from 1995-2006. As part 
of a broader parent study on infections and PSA, participants were also required to have at least 
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four serum specimens available in the DoDSR, one collected from each of the following four 
time periods: 1995-1997, 1998-2000, 2001-2003, and 2004-2006 (Supplemental Figure 1). This 
criterion was included to ensure generally similar availability of specimens and correlates of 
specimen availability across all studies. IM cases were defined as men with at least one inpatient 
diagnosis or two outpatient diagnoses of IM (ICD-9-CM code 075) within 30 days of each other 
from 1998-2003 (n=55). We selected these criteria to increase the specificity of the case 
definition for IM, as symptoms of IM can overlap with those of other infections, such as the 
common cold. We defined controls as men with no recorded IM diagnoses in their medical 
record as of 2006. We also required controls not to have any STI diagnoses (ICD-9-CM 090-
099.9 and 131), except for persistent viral infections (ICD-9-CM 054 and 078.1), in their medical 
record to allow them to be used in multiple analyses, including a previous study of STIs.15 
Although this restriction was not made for IM cases, no selection bias was introduced by this 
control criterion because none of the IM cases had STI diagnoses in their medical record. 
Finally, as part of the parent study, controls were frequency-matched to the entire case group (IM 
and STI cases) by race (n=255). 
For each IM case, we selected two serum specimens from the DoDSR, a pre-IM 
specimen (“pre-index”) and an acute or post-IM specimen (“index”). The pre-index specimen 
was defined as the first specimen collected at least 6 weeks before their diagnosis to account for 
the typical incubation period of IM18 (range: 46 days-4 years before diagnosis). The index 
specimen was defined as the first specimen collected seven days before to any time after their 
diagnosis (range: 1 day-3 years after diagnosis). Two specimens were also selected for each 
control, one randomly-selected from either 1998-2000 or 2001-2003 depending on the window 
of case diagnosis (“index” specimen), and the first specimen collected immediately before their 
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index specimen (“pre-index” specimen). Controls were additionally frequency-matched to cases 
by time of index specimen collection. 
As IM contributes to systemic in addition to organ-specific inflammation, we also 
performed a post-hoc analysis of other infectious diseases and PSA to begin to explore the 
specificity of observed associations for prostate inflammation/cell damage as opposed to 
systemic or other non-prostate inflammation. Cases for this analysis were men with a confirmed 
or unconfirmed diagnosis of fever or an infection associated with systemic (e.g., influenza, ICD-
9-CM 487) or localized non-genitourinary inflammation (e.g., streptococcal sore throat, ICD-9-
CM 034) from 1995-2006. Infections associated with minimal inflammation were not included 
(e.g., dermatophytosis, ICD-9-CM 110). Other infectious disease cases were required to have an 
available serum specimen collected seven days before up to one year after their infectious 
disease diagnosis based on our findings for IM (described below). All original controls, as well 
as STI and IM cases, were eligible to serve as other infectious disease cases, as long as their 
other infectious disease diagnosis occurred before their index STI or IM diagnosis. Original 
controls who did not meet the definition for infectious disease cases were included as controls.  
For each other infectious disease case, we selected two specimens, the first collected 
seven days before up to one year after their infectious disease diagnosis (index specimen, range: 
0-359 days after diagnosis), as well as the preceding specimen (pre-index specimen, range: 172 
days-7 years before diagnosis). We also selected two specimens for each control. These 
specimens were collected in the same windows of time as the case specimens. Controls were 
individually-matched to cases by race and window of index specimen collection (1995-1997, 
1998-2000, 2001-2003, and 2004-2006). 
This study was approved by the institutional review boards at the Walter Reed Army 
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Institute of Research and the Johns Hopkins Bloomberg School of Public Health. All data and 
specimens were anonymized before release from the DoDSR.  
Measurement of PSA concentration 
As participants were too young for routine prostate cancer screening and thus did not 
have PSA measurements in their military medical record, we measured total PSA concentration 
at Johns Hopkins using the Access Hybritech PSA assay (Beckman Coulter, Brea, CA). 
Specimens from the same individual were tested adjacent to one another in random within-
person order. We determined assay reproducibility by including 25 blinded quality control pairs 
from the DoDSR in the testing sequence (coefficient of variation=12.4%, and 6.9% after 
excluding one largely discrepant pair). 
Statistical analysis 
We explored PSA change between the pre-index and index specimens by calculating 
geometric and arithmetic mean pre-index and index PSA for cases and controls by linear 
regression with robust variance estimation. Values were adjusted for race and window of 
specimen collection to account for frequency- and individual-matching. We compared mean 
values by linear regression with robust variance estimation for the IM analysis and by 
conditional logistic regression for the post-hoc other infectious disease analysis. We further 
explored PSA change between cases and controls by calculating race- and time-adjusted 
categories of absolute and relative change using linear regression, and we compared these values 
by logistic regression with adjustment for race and window of specimen collection for the IM 
analysis, and by conditional logistic regression for the other infectious disease analysis. As in our 
previous studies,14,15 we defined a large PSA rise as a ≥40% increase in PSA between the pre-
index and index specimens. However, we also explored a definition based on the upper end of 
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the absolute change distribution (≥0.2 ng/mL), which we selected to generate approximately 
equal proportions of controls defined as having a large absolute and relative rise, and thus 
approximately equal power to detect a difference between cases and controls in both analyses. 
Finally, we also adjusted the results for age and time between the pre-index and index 
specimens. We did not adjust for body mass index (BMI) as a marker of overweight and obesity, 
which is also known to influence PSA levels,19 because U.S. active duty military members are 
required to maintain their weight below age-specific percent body fat cut-off points and, if they 
exceed these limits, are enrolled in mandatory weight-control programs;20 therefore, very few 
military members in our sample should have been overweight or obese. 
To investigate possible differences in findings by time between diagnosis and index 
specimen collection, and by major infectious disease category (unspecified viral, gastrointestinal 
tract, and respiratory tract infection in the other infectious disease analysis), we included 
interaction terms in the model and evaluated their statistical significance by the likelihood ratio 
test. To investigate the susceptibility of our findings to additional diagnosed or possibly 
undiagnosed infections not taken into consideration in the analyses, we repeated the analyses 
excluding: 1) men with other infectious or genitourinary diagnoses (e.g., urinary tract infection, 
site not specified; ICD-9-CM 599) preceding their pre-index specimen or between their pre-
index and index specimens for the IM analysis, and men with genitourinary diagnoses preceding 
their pre-index specimen or between their pre-index and index specimen for the other infectious 
diseases analysis; 2) men with “clinically-indicated” or “STI visit” reasons for blood draw for 
their pre-index or index specimens; 3) men with small breaks (<60 days) in active duty status 
between their pre-index and index specimens; 4) men deployed between these two specimens, as 
their medical records might be less complete during this time; and 5) higher rank officers who 
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may have greater access to non-military health care. Finally, to investigate the influence of 
control selection on our findings (i.e., chance assignment of particular controls to particular 
cases, as each control could, in theory, serve as a control for any case of the same race), we re-
sampled controls nine additional times and compared the results to the main analysis.  
 
RESULTS 
Young adult-onset IM 
We identified 55 IM cases who met study criteria and selected 255 controls for 
comparison. Compared to controls, cases were slightly younger and were more likely to be 
Caucasian because controls were frequency-matched to the entire group of STI and IM cases 
rather than only to IM cases (Table 1). Cases also had a greater length of time between their pre-
index and index specimens than controls. Considering change in PSA between the pre-index and 
index specimens, although cases had a similar average change in PSA than controls, they were 
significantly more likely to have a large rise in PSA at the time of their index specimen than 
controls, as defined by both a large absolute and relative rise in PSA (≥0.2 ng/mL rise: 19.7% 
versus 8.8%, p=0.027; ≥40% rise: 25.7% versus 9.4%, p=0.0021, Table 2). When these results 
were investigated by time between IM diagnosis and index specimen collection, cases whose 
index specimen was collected within 3 months of diagnosis were no more likely to have a large 
rise in PSA than controls; those whose specimen was collected 4-12 months after diagnosis were 
significantly more likely to have a large PSA rise than controls; and those whose index specimen 
was collected >1 year after diagnosis were slightly, non-significantly more likely to have a large 
PSA rise than controls, at least for a large relative change (p-interaction=0.0002, 0.0003, Table 
3). 
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Similar results were observed in sensitivity analyses designed to reduce the possible 
influence of additional diagnosed or undiagnosed infections on our findings (≥0.2 ng/mL rise:  
p=0.027-0.065; ≥40% rise: p=0.0028-0.019) and in repeated control sampling (p=0.030-0.12, 
0.0026-0.016). 
Other infectious diseases 
To begin to explore the specificity of observed associations for prostate inflammation/cell 
damage as opposed to systemic or other non-prostate inflammation, we performed a post-hoc 
analysis of other infectious diseases. We identified 90 infectious disease cases who met study 
criteria: 13 cases of streptococcal sore throat (ICD-9-CM 034.0), five influenza (ICD-9-CM 
487.1, 487.8), one Haemophilus influenzae infection (ICD-9-CM 041.5), 14 intestinal infection 
due to specified or unspecified organisms (ICD-9-CM 008.43, 008.69, 008.8, 009.0), 46 
unspecified viral infection (ICD-9-CM 079.99), two other specified viral infection (ICD-9-CM 
079.89), two unspecified infectious and parasitic diseases (ICD-9-CM 136.9), four fever not 
accompanied by another diagnosis (ICD-9-CM 780.6), two chicken pox (ICD-9-CM 052.9, 
053.0), and one leptospirosis icterohemorrhagica (ICD-9-CM 100.0). 220 of the original 255 
controls met the eligibility criterion for comparison. In crude analyses, infectious disease cases 
had a significantly greater average change in PSA between their pre-index and index specimens 
than controls, and were more likely to have both a large absolute and relative rise in PSA. These 
findings attenuated, however, after adjustment for age and time between specimens, although 
they remained statistically significant for a large absolute rise in PSA (≥0.2 ng/mL rise: 25.7% 
versus 14.0%, p=0.020; ≥40% rise: 27.7% versus 18.0%, p=0.092, Table 4). After standardizing 
these values to the same distribution of time between specimens as for the IM analysis, these 
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proportions were 14.8% versus 3.1% for a ≥0.2 ng/mL rise, and 19.2% versus 9.5% for a ≥40% 
rise in PSA. 
Generally similar results were observed for cases whose index specimen was collected 
within 3 or 4-12 months of diagnosis (p-interaction=0.13, 0.48), and for unspecified viral, 
gastrointestinal tract, and respiratory tract infection cases (p-interaction=0.90, 0.45, Table 5). 
Generally similar results were also observed in all sensitivity analyses (≥0.2 ng/mL rise: 
p=0.018-0.077; ≥40% rise: p=0.029-0.18), except for the analysis excluding officers (p=0.22, 
0.76), and with repeated control sampling (p=0.0003-0.036, 0.032-0.23). 
 
DISCUSSION 
In our U.S. military-based study, we found that young men with adult-onset IM were 
more likely to have a large rise in PSA during or following infection than controls, as were 
young men with other infectious diseases not known to involve the prostate. To our knowledge, 
our study is the first to investigate the influence of these infections on PSA.  
Given our positive findings for other infectious diseases, an important question to ask for 
both our IM and previous exudative STI results14,15 is the likelihood that these findings reflect 
prostate involvement during infection ‒ our original interpretation of PSA elevation ‒ versus 
other possible mechanisms of PSA elevation. Comparing the magnitude of associations across 
infections (Table 6), we observed the strongest association for chlamydia, an exudative STI with 
known potential to infect the prostate;9 and weaker associations of similar magnitude for 
gonorrhea, another STI with known potential to infect the prostate,9 as well as for IM and other 
infectious diseases not known to involve the prostate. Therefore, one potential interpretation of 
these findings could be that PSA may rise for multiple, possibly cumulative reasons, including: 
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1) prostate involvement (in the case of chlamydia and, to a lesser degree, possibly also gonorrhea 
and IM), and 2) other mechanisms related more generally to infection and inflammation (in the 
case of all infections studied). Based on this interpretation, prostate involvement may occur in a 
maximum of 25-27% of chlamydial infections15 (Table 6) to a minimum of 15% of chlamydial 
infections (minus 9.7-11.7% for the difference between other infectious disease cases and their 
respective controls). By the same logic, these numbers are 10-12% to 0-1% for gonococcal 
infections, and 11-16% to 0-6% for IM episodes. Why PSA did not raise for non-chlamydial, 
non-gonococcal urethritis cases who, by definition, have urethral inflammation is unclear.   
Other important questions raised by our analysis are possible non-prostate infection-
related reasons for PSA elevation in young men. Although PSA has been detected in some extra-
prostatic glands/organs (e.g., salivary glands/saliva,21-26 kidney,22,24 and pancreas22-24), we 
believe that PSA secretion by these infected glands/organs is unlikely to explain our findings 
because these extra-prostatic sites produce considerably less PSA than the prostate (<1%22). 
Instead, we believe that a systemic inflammatory contribution to PSA elevation is more likely. 
Under normal circumstances, PSA is produced by prostate epithelial cells and is secreted into the 
prostatic lumen to liquefy semen. However, when the prostate epithelial barrier is disrupted, such 
as by cell damage, PSA can leak into the extracellular space and, ultimately, into circulation. 
This leakage is facilitated by inflammation, which makes blood vessels more permeable to 
immune cells, as well as to small molecules, such as PSA.27 Our previous interpretation of PSA 
elevation focused on localized prostate inflammation and cell damage in the context of prostate 
infection,14,15 but it is conceivable that systemic inflammation might also contribute to PSA 
elevation, either through inflammation-mediated prostate cell damage and increased vascular 
permeability, or through increased vascular permeability in the context of pre-existing prostate 
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epithelial cell damage/disruption from other sources. Under this latter hypothesis, approximately 
10% of young men might be expected to have prostate epithelial disruption at any single point in 
time based on our other infectious disease findings.  
Our findings for IM, but not for other infectious diseases, varied by time since diagnosis. 
Results were null for men whose index specimen was collected most recently after diagnosis and 
strongly positive for men whose index specimen was collected later after diagnosis. While 
speculative, one possible explanation for this temporal association may be changes in the type 
and level of activity of convalescent men over time. Immediately following diagnosis or 
symptom onset, fatigued IM patients likely spend more time resting, which has been found to 
reduce PSA in hospitalized patients,28 and less time engaging in sexual and physical activity, 
which have been found to increase PSA in some studies.29-31 However, as men regain their 
energy later in their convalescence, it is possible they engage in these activities to a greater 
degree, leading to the stronger observed association from four months post-diagnosis onwards. 
Thus, the potential influence of IM-mediated systemic inflammation on PSA may be counter-
balanced by immediate post-diagnosis rest and enhanced by later increases in activity, which 
likely eventually return to pre-IM levels.   
Additional questions raised by our findings include the long-term persistence of 
infection-mediated PSA elevation, which is of interest given observed associations between PSA 
concentration at a younger age and later prostate cancer risk,32-34 and the generalizability of our 
findings to middle- and older-aged men undergoing PSA screening. Although routine PSA 
testing for early prostate cancer detection received a grade D recommendation from the U.S. 
Preventive Services Task Force,35 this question remains of interest for several reasons. First, 
informed and targeted PSA testing for early prostate cancer detection is still supported by several 
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organizations,36-40 and is still frequently performed despite guideline changes.41 Second and more 
relevant to our findings, some organizations now support initiating PSA testing at a younger age 
than previously recommended (i.e., beginning at 40-45 rather than 50-55 years of age) to 
establish a baseline PSA value and to stratify men by their future prostate cancer risk and 
consequent prostate cancer screening regimen.39,40 Thus, whether a recent infection, such as a 
cold, influences PSA levels in middle- and older-aged men may be relevant for current and 
future PSA screening paradigms. 
Based on our findings in younger men, we would expect at least 10% of middle- to older-
aged men to have a rise in PSA of at least 0.2 ng/mL during or following an infection. 
Depending on their initial PSA value, this small magnitude of change might be sufficient to 
influence screening regimens in men in their 40s (recommended threshold of 1.0 ng/mL),39,40 but 
would be unlikely to influence the decision to biopsy unless men were close to the threshold 
(recommended threshold of 2.5-4 ng/mL).42,43 However, if the magnitude of PSA change is 
greater in middle- and older-aged men than in younger men, as might be expected based on their 
likely greater degree of pre-existing epithelial cell disruption and amount of PSA secreted, then 
these larger possible rises might be sufficient to influence both screening and biopsy decisions, 
and thus might be worth pursuing in future research. Additionally, whether or not non-infectious, 
inflammatory conditions, such as inflammatory bowel disease, influence serum PSA levels might 
also be of interest, but these have been examined in only a few small studies of hepatitis44-49 and 
periodontitis.50 We could not address this question in the present study because our original data 
request was limited to infectious disease and genitourinary ICD-9-CM codes consistent with our 
original hypothesis, and because our de-identified data can no longer be linked to the master 
DoDSR file. 
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In summary, we found that PSA rose during or following an episode of IM, a condition 
with possible prostate involvement, as well as during or following other inflammatory infectious 
diseases not known to involve the prostate, such as influenza. Taken together with our previous 
findings for chlamydia and gonorrhea,14,15 these findings suggest that PSA may rise for multiple 
possibly cumulative reasons, including prostate infection, inflammation and cell damage, as well 
as systemic inflammation. Additional questions raised by our findings are the long-term 
persistence of elevated PSA years to decades following resolution of infection and the 
generalizability of our findings to middle- and older-aged men undergoing PSA screening.       
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Table 1:  Demographic characteristicsa of 55 young, male infectious mononucleosis cases and 255 
controls; U.S. military 1995-2006 





Mean age (years)c 28.4 29.8 <0.0001 
Race (%):d    
African-American 16.4 55.3  
Caucasian 78.1 36.0 <0.0001 
Other 5.5 8.6  
Marital status (%):c    
Married 73.7 79.1 
0.40 
Other 26.3 20.9 
Military grade (%):c    
Enlisted 95.2 91.0 
0.35 
Officer 4.8 9.0 
Reason for blood draw (%):c    
Routinee 79.7 70.4  
Clinically indicated/part of an STI visitf 2.6 1.3 0.25 
Other/unknown 17.8 28.3  
Mean number of blood draws for HIV-1 testing 
from 1995 to 2006 10.0 9.8 0.52 
Mean time between pre-index and index 
specimens (months) 23.5 18.8 0.0073 
IM=infectious mononucleosis; HIV-1=human immunodeficiency virus type 1; STI=sexually transmitted infection 
a  Values for cases and controls were calculated by linear regression adjusting for race (African-American, non-
African-American) and window of specimen collection. 
b P-values were calculated by linear regression for continuous or binary variables, and by logistic regression for 
categorical variables. All models were adjusted for race (African-American, non-African-American) and 
window of specimen collection 
c At the time of blood draw of the index specimen. 
d Cases were frequency-matched to controls (also used for STI cases) by race/ethnicity. 
e  Indicates blood drawn for routine and pre- and post-deployment HIV-1 tests, as well as HIV-1 tests performed 
as part of specialized physical examinations (e.g., for flight school). 
f Indicates blood drawn for self or clinical suspicion of HIV-1 or STIs, as well as from hospitalized patients or 
those visiting emergency rooms for certain clinical indications. Blood draws are coded as “clinically 
indicated/part of an STI visit” irrespective of the results of HIV-1 or STI testing. 
 
Table 2:  Pre-index and index serum total prostate-specific antigen concentration for 55 young, male 
infectious mononucleosis cases and 255 controls; U.S. military 1998-2003 





PSA (ng/mL) Pre-index Index Pre-index Index p-valuea 
Geometric meanb  0.58 0.61 0.55 0.56 0.66 
Meanb 0.67 0.70 0.65 0.65 0.53 
Interquartile rangec 0.35-0.85 0.42-0.98 0.38-0.76 0.38-0.79  
Absolute change in serum total PSA (%):b 
≤0.00 ng/mL 48.4 52.1  
0.01-0.09 ng/mL 17.0 23.8  
0.10-0.19 ng/mL 14.5 15.2  
0.20-0.29 ng/mL 8.8 3.4 0.26 
0.30-0.39 ng/mL 0.8 2.1  
0.40-0.49 ng/mL 4.6 1.3  
≥0.50 ng/mL 5.9 2.0  
Large absolute rise in serum total PSA (%):b   
≥0.2 ng/mL 20.1 8.9 0.014 
≥0.2 ng/mLd 19.7 8.8 0.027 
Relative percent change in serum total PSA (%):b 
≤0  48.4 52.1  
0.1-9 12.2 11.3  
10-19 7.6 12.3  
20-29 5.2 10.2 0.25 
30-39 2.6 4.8  
40-49 9.9 1.8  
≥50 14.1 7.6  
Large relative rise in serum total PSA (%):b   
≥40 24.0 9.4 0.0025 
≥40d 25.7 9.4 0.0021 
IM=infectious mononucleosis; PSA=prostate-specific antigen 
a P-values were calculated by linear regression with robust variance estimation for continuous variables, linear 
regression for binary variables, and logistic regression for categorical variables. All models were adjusted for 
race (African-American, non-African-American) and window of specimen collection.   
b Values were calculated by linear regression with robust variance estimation for continuous variables, and by 
linear regression for binary and categorical variables. All models were adjusted for race and window of 
specimen collection. 
c Not adjusted for race or window of specimen collection.  
d Additionally adjusted for age and time between pre- and index specimens.  
Table 3:  Change in serum total prostate-specific antigen concentration (ng/mL) for young, male infectious mononucleosis cases and 
controls, stratified by time between diagnosis and index specimen collection; U.S. military 1998-2003 
 Absolute change in serum total PSAa Relative percent change in serum total PSAa 
 Cases Controls  Cases Controls  
 N ≥0.2 ng/mL (%) N ≥0.2 ng/mL (%) p-value N ≥40% (%) N ≥40% (%) p-value 
Time between diagnosis and index specimen collection:       
<4 months 19 10.7 255 8.8 0.77 19 10.1 255 9.6 0.94 
4-12 months 19 43.3 245 8.4 <0.0001 19 49.0 245 8.9 <0.0001 
≥12 months 17 15.7 150 13.6 0.80b 17 25.5 150 13.1 0.13c 
 
PSA=prostate-specific antigen 
a  All values and p-values were calculated by linear regression adjusting for race, window of specimen collection, age, and time between pre- and index 
specimens. 






Table 4:  Pre-index and index serum total prostate-specific antigen concentration for 90 young male 
infectious disease cases and 220 individually-matched controls; U.S. military 1995-2006 





PSA (ng/mL) Pre-index Index Pre-index Index p-valueb 
Geometric meanc  0.54 0.57 0.51 0.70 0.0029 
Meanc 0.63 0.67 0.65 0.79 0.23 
Interquartile ranged 0.37-0.76 0.39-0.78 0.36-0.79 0.41-0.93  
Absolute change in serum total PSA (%):c 
≤0.00 ng/mL 37.4 44.3  
0.01-0.09 ng/mL 21.5 28.3  
0.10-0.19 ng/mL 13.6 15.1  
0.20-0.29 ng/mL 10.4 4.7 0.034 
0.30-0.39 ng/mL 5.4 0.4  
0.40-0.49 ng/mL 2.8 1.6  
≥0.50 ng/mL 8.9 5.5  
Large absolute rise in serum total PSA (%):c   
≥0.2 ng/mL 27.6 12.2 0.0023 
≥0.2 ng/mL e 25.7 14.0 0.020 
Relative percent change in serum total PSA (%):c 
≤0  37.5 44.8  
0.1-9 10.3 15.0  
10-19 12.9 12.1  
20-29 3.3 6.4 0.18 
30-39 6.5 5.3  
40-49 5.7 5.1  
≥50 23.8 11.2  
Large relative rise in serum total PSA (%)c 
≥40 29.5 16.3 0.012 
≥40e 27.7 18.0 0.092 
PSA=prostate-specific antigen 
a Includes men with the following diagnoses: streptococcal sore throat (ICD-9-CM 034.0), influenza (487.1, 
487.8), Haemophilus influenzae infection (041.5), intestinal infection due to specified or unspecified organisms 
(008.43, 008.69, 008.8, 009.0), unspecified viral infection (079.99), other specified viral infection (079.89), 
unspecified infectious and parasitic diseases (136.9), fever not accompanied by another diagnosis (780.6), 
chicken pox (052.9, 053.0), and leptospirosis icterohemorrhagica (100.0). 
b P-values were calculated by conditional logistic regression.   
c Values were calculated by linear regression adjusting for race (African-American, non-African-American) and 
window of specimen collection. 
d Not adjusted for race or window of specimen collection. 
e Additionally adjusted for age and time between pre- and index specimens.
Table 5:  Change in serum total prostate-specific antigen concentration (ng/mL) for young male infectious disease cases and individually-
matched controls, stratified by time between diagnosis and index serum specimen collection, and infection type; U.S. military 1995-
2006 
 Absolute change in serum total PSA Relative percent change in serum total PSA 
 Cases Controls  Cases Controls  
 N ≥0.2 ng/mL (%)a N ≥0.2 ng/mL (%)a p-valueb N ≥40% (%)a N ≥40% (%)a p-valueb 
Time between diagnosis and index specimen collection:       
<4 months 33 26.1 83 16.4 0.62 33 30.9 83 19.2 0.53 
4-12 months 57 25.6 136 12.5 0.007c 57 26.0 136 17.3 0.08d 
Type of infection:           
   Unspecified viral  48 24.1 115 12.6 0.11 48 25.3 115 16.4 0.42 
   Gastrointestinal tract 14 31.0 34 13.7 0.20 14 38.7 34 14.9 0.08 
   Respiratory tract 19 31.0 50 19.4 0.26e 19 32.0 50 25.8 0.51f 
 
PSA=prostate-specific antigen 
a Values were calculated by linear regression adjusting for race, window of specimen collection, age, and time between pre- and index specimens. 
b P-values were calculated by conditional logistic regression adjusting for age and time between pre- and index specimens. 
c  P-value for interaction=0.13. 
d  P-value for interaction=0.48. 
e  P-value for interaction=0.90. 









Table 6:  Absolute and relative risks of large serum total prostate-specific antigen concentration (ng/mL) rises during or following infection 
among young male military members by infection type; U.S. military 1995-2006 
 PSA rise ≥0.2 ng/mL PSA rise ≥40% 
 



















































IM=infectious mononucleosis; NCNGU=non-chlamydial, non-gonococcal urethritis; PSA=prostate-specific antigen 
a Further details and complete results for these infectious diseases are presented in reference 15. 
b Includes men with the following diagnoses: streptococcal sore throat (ICD-9-CM 034.0), influenza (487.1, 487.8), Haemophilus influenzae infection 
(041.5), intestinal infection due to specified or unspecified organisms (008.43, 008.69, 008.8, 009.0), unspecified viral infection (079.99), other specified 
viral infection (079.89), unspecified infectious and parasitic diseases (136.9), fever not accompanied by another diagnosis (780.6), chicken pox (052.9, 
053.0), and leptospirosis icterohemorrhagica (100.0) 
 
Supplemental Figure 1:  IM and other infectious disease case and control selection, US 
military 1995-2001. 
 
All participants were required to have at least four serum specimens available in the Department 
of Defense Serum Repository (DoDSR), one collected from each of the following four time 
periods: 1995-1997, 1998-2000, 2001-2003, and 2004-2006. IM cases were defined as men with 
at least one inpatient IM diagnosis or two outpatient diagnoses within 30 days of each other from 
either 1998-2000 or 2001-2003 (solid blue line). For each of these cases, we selected two serum 
specimens, one collected at least six weeks before their diagnosis and one collected after their 
diagnosis. Controls for IM cases were defined as men with no IM (or sexually transmitted 
infection (STI)) diagnoses in their medical record from 1995-2006. For each control, two 
specimens were selected, one randomly-selected from either 1998-2000 or 2001-2003, 
depending on the window of case diagnosis, as well as their previous specimen. These men were 
frequency-matched to cases by race and window of index specimen ascertainment, i.e., 1998-
2000 or 2001-2003.  
 
Other infectious disease cases were defined as men with a confirmed or unconfirmed diagnosis 
of fever or an infection associated with systemic or localized non-genitourinary inflammation 
from 1995-2006. All original controls, as well as IM cases and STI cases from a previous 
analysis, were eligible to serve as other infectious disease cases, as long as their other infectious 
disease diagnosis occurred before their index IM or STI diagnosis. Therefore, the window of 
other infectious disease case ascertainment for original IM and STI cases could be limited to 
1995-1998 (solid blue line) or could extend almost up to the end of 2003, depending on the date 
of their original IM or STI diagnosis (striped blue line). The other infectious disease diagnosis 
for original controls could occur at any time from 1995-2006 (solid blue line). Two specimens 
were selected for each case, one collected before their diagnosis and one collected within one 
year after their diagnosis. Original controls who did not meet the criteria for an other infectious 
disease case were considered to be other infectious disease controls. Two specimens were also 
selected for each of these men in the same windows of time as the case specimens. Controls were 
individually matched to other infectious disease cases by race and window of case ascertainment 











Window of IM case ascertainment
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Supplemental Figure 1:  IM and other infectious disease case and control 
selection, U.S. military 1995-2006
IM=infectious mononucleosis; STI=sexually transmitted infection
 
 
